AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC Pharmaceuticals to research chronic disease ...

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

The pharmaceutical drug company AstraZeneca filed a lawsuit against the Utah attorney general claiming Utah's new law on limiting prescription drug prices goes against a federal program.

A Google Translate screenshot correctly shows that the name of the pharmaceutical company AstraZeneca, when written as “A stra ze neca,” means “a road to death” in Latin.

Tariffs are "certainly not material long term," Soriot said, adding that AstraZeneca will rely on the existing global network to shift manufacturing as needed.

AstraZeneca has made an upfront payment to Alteogen and may make additional payments, conditional on achievement of specific development, regulatory and sales-related milestones.

The AstraZeneca property is split by Del. 141. A bridge connects what the firm calls its north and south campuses. The document filed in the county deeds office updates the legal responsibilities ...

Covington & Burling's London operation has advised pharmaceuticals giant AstraZeneca on its $1 billion acquisition of EsoBiotec, a Belgian biotechnology company specialising in vivo cell therapies.

AstraZeneca move leaves Reeves under the weather The government may have strong arguments for denying AstraZeneca's demands, but they may be harder to sustain given the sector - high-growth life ...

AstraZeneca scraps £450m vaccine plant in Liverpool after Labour funding cut The pharmaceutical giant says the new Labour government has offered less investment than their Conservative predecessors.

AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient, the latter said ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate Dato-DXd has again failed to improve overall survival in a phase 3 trial.